Viewing Study NCT07221695


Ignite Creation Date: 2025-12-24 @ 1:21 PM
Ignite Modification Date: 2026-01-14 @ 4:05 AM
Study NCT ID: NCT07221695
Status: ENROLLING_BY_INVITATION
Last Update Posted: 2025-10-28
First Post: 2025-10-12
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Embolization Strategies for Pelvic Venous Disorders: Foam + Glue vs Foam + Coils
Sponsor:
Organization:

Raw JSON

{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D004659', 'term': 'Enbucrilate'}], 'ancestors': [{'id': 'D003487', 'term': 'Cyanoacrylates'}, {'id': 'D000179', 'term': 'Acrylates'}, {'id': 'D000144', 'term': 'Acids, Acyclic'}, {'id': 'D002264', 'term': 'Carboxylic Acids'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D009570', 'term': 'Nitriles'}, {'id': 'D011108', 'term': 'Polymers'}, {'id': 'D046911', 'term': 'Macromolecular Substances'}, {'id': 'D001697', 'term': 'Biomedical and Dental Materials'}, {'id': 'D014014', 'term': 'Tissue Adhesives'}, {'id': 'D008420', 'term': 'Manufactured Materials'}, {'id': 'D013676', 'term': 'Technology, Industry, and Agriculture'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 60}}, 'statusModule': {'overallStatus': 'ENROLLING_BY_INVITATION', 'startDateStruct': {'date': '2025-08-25', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-10', 'completionDateStruct': {'date': '2025-12-25', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-10-25', 'studyFirstSubmitDate': '2025-10-12', 'studyFirstSubmitQcDate': '2025-10-25', 'lastUpdatePostDateStruct': {'date': '2025-10-28', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-10-28', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2025-08-25', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'compare the clinical efficacy of ovarian vein embolization using combined foam plus N-butyl cyanoacrylate (Gluebran®️) versus combined foam plus detachable coils', 'timeFrame': '18 months', 'description': '2\\. Symptom severity reduction, assessed by the Pelvic Venous Clinical Severity Score (PVCSS) at baseline, 3, 6, 12, and 18 months.'}]}, 'oversightModule': {'isUsExport': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'conditions': ['Pelvic Congestive Syndrome']}, 'descriptionModule': {'briefSummary': 'Foam Plus Glue Versus Foam Plus Coils for Ovarian Vein Embolization in the Treatment of Pelvic Venous Disorders: A Randomized Controlled Trial'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT'], 'maximumAge': '50 Years', 'minimumAge': '18 Years', 'genderBased': True, 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria\n\n* Female patients aged 18 to 50 years\n* Clinically suspected pelvic venous disorder (PVD), presenting with chronic pelvic pain ≥ 6 months\n* Pelvic pain intensity ≥ 4 on a 10-point Visual Analogue Scale (VAS) at baseline\n* No evidence of significant venous obstruction or internal iliac insufficiency\n* Willingness to participate, provide written informed consent, and comply with study visits and procedures exclusion criteria\n* Pregnancy or planning to conceive within the next 12 months\n* Significant Nutcracker syndrome diagnosed by duplex / CTV / MRV\n* Significant May-Thurner syndrome diagnosed by duplex / CTV / MRV\n* Non-ovarian sources of reflux requiring intervention, including internal iliac vein insufficiency; During venography all patients will undergo selective pelvic venography prior embolization to exclude patients who have combined gonadal and internal iliac vein reflux)\n* History of previous pelvic vein embolization or surgical ligation\n* Coagulopathy, defined as:\n\n * INR \\> 1.5\n * Platelet count \\< 50 × 10⁹/L\n* Severe comorbidities, including:\n\n * Active pelvic infection (e.g., pelvic inflammatory disease)\n * End-stage renal disease (eGFR \\< 30 mL/min/1.73 m²)\n * Decompensated heart failure (NYHA class III-IV)\n * Active malignancy requiring treatment\n\nKnown allergy or hypersensitivity to:\n\n* Iodinated contrast media\n* Polidocanol (Aethoxysklerol®)\n* N-butyl cyanoacrylate (e.g., Gluebran® 2)\n* Nickel, platinum, or stainless steel (components of embolization coils) . Presence of non-venous pelvic pathology requiring immediate management'}, 'identificationModule': {'nctId': 'NCT07221695', 'acronym': 'foam and coil', 'briefTitle': 'Embolization Strategies for Pelvic Venous Disorders: Foam + Glue vs Foam + Coils', 'organization': {'class': 'OTHER', 'fullName': 'Kafrelsheikh University'}, 'officialTitle': 'Foam Plus Glue Versus Foam Plus Coils for Ovarian Vein Embolization in the Treatment of Pelvic Venous Disorders:', 'orgStudyIdInfo': {'id': 'glue vs coil for ovarian ttt'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Embolization using polidocanol foam followed by N-butyl cyanoacrylate', 'description': '. After selective catheterization of the ovarian vein and reflux confirmation, Sclerosant foam will be prepared using 3% polidocanol (Aethoxysklerol®, Kreussler Pharma), mixed with room air in a 1:4 ratio (1 mL polidocanol to 4 mL air) using the Tessari double-syringe technique, creating a dense and stable foam. The foam will be injected slowly into the reservoir of the refluxing segment of the ovarian vein under fluoroscopic guidance to induce endothelial irritation and reduce venous flow. A total of 5-10 mL of 3% polidocanol foam will be injected per vein, adjusted based on vein diameter and reflux length.\n\nNext, N-butyl cyanoacrylate (Gluebran®️ 2) will be mixed with Lipiodol in a 1:2 to 1:3 ratio, depending on vein size and flow rate. Approximately 1-2 mL of the glue mixture will be injected per vein using a coaxial microcatheter system from distal to proximal segments. Occlusion will be confirmed by post-embolization venography."', 'interventionNames': ['Other: Foam + N-butyl Cyanoacrylate']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Combined Foam Sclerotherapy and Detachable Coil Embolization', 'description': 'Patients in this group will undergo embolization using sclerosant foam followed by detachable platinum coils. Vascular access and catheterization technique will mirror Group A.\n\nAfter injecting polidocanol foam (as above), subsequently, detachable platinum fibered coils - specifically Interlock™ (Boston Scientific) or Concerto™ (Medtronic) - will be deployed to achieve permanent mechanical occlusion. Coil selection (diameter and length) will be based on intra-procedural vein sizing. Final occlusion will be confirmed via completion venography.', 'interventionNames': ['Other: Combined Foam Sclerotherapy and Detachable Coil Embolization']}], 'interventions': [{'name': 'Foam + N-butyl Cyanoacrylate', 'type': 'OTHER', 'description': '3% polidocanol (Aethoxysklerol®, Kreussler Pharma), mixed with room air in a 1:4 ratio (1 mL polidocanol to 4 mL air) using the Tessari double-syringe technique, creating a dense and stable foam.', 'armGroupLabels': ['Embolization using polidocanol foam followed by N-butyl cyanoacrylate']}, {'name': 'Combined Foam Sclerotherapy and Detachable Coil Embolization', 'type': 'OTHER', 'description': 'polidocanol foam (as above), subsequently, detachable platinum fibered coils - specifically Interlock™ (Boston Scientific) or Concerto™ (Medtronic)', 'armGroupLabels': ['Combined Foam Sclerotherapy and Detachable Coil Embolization']}]}, 'contactsLocationsModule': {'locations': [{'zip': '33511', 'city': 'Kafr ash Shaykh', 'state': 'Kafrelshaykh Governorate', 'country': 'Egypt', 'facility': 'Kafr El Shaykh University', 'geoPoint': {'lat': 31.11174, 'lon': 30.93991}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Kafrelsheikh University', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'principal investigator', 'investigatorFullName': 'Moustafa Hassan Mabrouk Abdelhameed', 'investigatorAffiliation': 'Kafrelsheikh University'}}}}